Ignite Creation Date:
2024-05-06 @ 5:53 PM
Last Modification Date:
2024-10-26 @ 2:37 PM
Study NCT ID:
NCT05461807
Status:
COMPLETED
Last Update Posted:
2022-10-26
First Post:
2022-07-14
Brief Title:
An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins Venous Thromboembolism
Sponsor:
Bayer
Organization:
Bayer
Organization Data
Organization:
Bayer
Class:
INDUSTRY
Study ID:
22290
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Bayer
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Janssen Research Development LLC | INDUSTRY |